Adenoid Cystic Carcinoma of the Nasopharynx with Skull Base Involvement: Retrospective National Cohort Analysis of Treatment Paradigms, Outcomes, and Provider Density

Abstract

Objectives This article examines a national cohort of patients with nasopharyngeal adenoid cystic carcinoma (ACC) for incidence, skull base invasion, overall survival, and treatment paradigms.

Design, Setting, and Participants Retrospective national population-based study using Surveillance, Epidemiology, and End Results program data of patients with ACC of the nasopharynx (NACC) and skull base between 2004 and 2016.

Main Outcomes and Measures Primary outcomes included 5-year overall survival and odds of radiation treatment. Statistical analysis was performed using STATA 15.0 (STATACorp). p-Values < 0.05 were considered statistically significant.

Results Of the 2,385 cases of ACC, 70 cases were classified as NACC. Twenty-one percent (15) involved invasion of the skull base or posterior pharyngeal wall, and 42% (30) were either stage 3 or stage 4. The 5-year overall survival for patients with NACC without skull base invasion was 67% which dropped to 40% with invasion into the skull base. Radiation was used as the primary form of therapy for 62% of NACC and 73% of NACC invading into skull base. Odds of receiving radiation therapy and 5-year survival were not affected by socioeconomic status or density of providers.

Conclusion NACC is rare in incidence and was most commonly treated with radiation therapy when advanced in stage. Prognosis was dependent on invasion through posterior pharyngeal wall and skull base. Provider density and socioeconomic status did not affect odds of radiation or overall survival for NACC.

Keywords

nasopharyngeal malignancy - adenoid cystic carcinoma - skull base - radiation therapy - outcomes

• References

• 1 Afani L, Errihani H, Benchafai I, Lalami Y. Nasopharyngeal adenoid cystic carcinoma, a rare but highly challenging disease with unmet therapeutic needs: a case-report and review of the literature [in French]. Cancer Radiother 2016; 20 (05) 400-404
• 2 Gadkaree SK, Parikh A, Rodarte A, Lehmann A, Gray S, Lin D. Adenoid cystic carcinoma of the skull base: response to radiation therapy and outcomes in a retrospective case series. J Neurol Surg B Skull Base 2019; •••
• 3 Liu T-R, Yang A-K, Guo X. et al. Adenoid cystic carcinoma of the nasopharynx: 27-year experience. Laryngoscope 2008; 118 (11) 1981-1988
• 4 Duggan MA, Anderson WF, Altekruse S, Penberthy L, Sherman ME. The Surveillance, Epidemiology, and End Results (SEER) program and pathology: toward strengthening the critical relationship. Am J Surg Pathol 2016; 40 (12) e94-e102
• 5 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147 (08) 573-577
• 6 Cao C-N, Luo J-W, Xu G-Z, Gao L, Xu Z-G, Tang P-Z. Management of nasopharyngeal adenoid cystic carcinoma. J Oral Maxillofac Surg 2013; 71 (04) e203-e209
• 7 Ryckman JM, Kusi Appiah A, Simone II CB, Verma V. Treatment approaches for nasopharyngeal adenoid cystic carcinoma. Acta Oncol 2018; 57 (07) 995-1001
• 8 Alleyne CH, Bakay RA, Costigan D, Thomas B, Joseph GJ. Intracranial adenoid cystic carcinoma: case report and review of the literature. Surg Neurol 1996; 45 (03) 265-271
• 9 Gentile MS, Yip D, Liebsch NJ, Adams JA, Busse PM, Chan AW. Definitive proton beam therapy for adenoid cystic carcinoma of the nasopharynx involving the base of skull. Oral Oncol 2017; 65: 38-44
• 10 Takagi M, Demizu Y, Hashimoto N. et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck. Radiother Oncol 2014; 113 (03) 364-370
• 11 Gadkaree SK, McCarty JC, Siu J. et al. Variation in the geographic distribution of the otolaryngology workforce: a national geospatial analysis. Otolaryngol Head Neck Surg 2020; 162 (05) 649-657